Fundraising Fox
Umoja Biopharma, Inc.
Seattle, US · Founded 2019 · Delaware corporation · 248 employees on LinkedIn · 9 known investors
Find your way into Umoja Biopharma, Inc.
Sign up to see every warm intro you have to Umoja Biopharma, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Umoja Biopharma, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process. The company operates its own in-house manufacturing to supply its therapeutics.
Founders & leadership
Umoja Biopharma, Inc. was founded in 2019 by Andrew M. Scharenberg.
Board
Investors · 9
How we know: MPM BioImpact's portfolio page · the company's own site · a partner's Signal profile · Not right? Tell us
How we know: the company's own site · board seat on SEC Form D · funding news · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: K2 HealthVentures's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Funding
SEC filings, press & company announcements$210M disclosed across 1 of 2 rounds · 2021–2025
- Undisclosed amountSeries CJan 2025Source ↗
▶$210MraisedJun 2021 · 29 investors · BiotechnologyRule 506(b)
- Philip S. LowDirector
- Irena MelnikovaExecutive Officer
- Anna FrenchDirector
- Robert GlassmanDirector
- John HamerDirector
- Luke EvninDirector
- Andrew M. ScharenbergExecutive Officer, Director
- Offering amount
- $210M
- Amount sold
- $210M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Umoja Biopharma, Inc..
In the news
Frequently asked questions
- What does Umoja Biopharma, Inc. do?
- Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process. The company operates its own in-house manufacturing to supply its therapeutics.
- Who founded Umoja Biopharma, Inc.?
- Umoja Biopharma, Inc. was founded by Andrew M. Scharenberg in 2019.
- Who are Umoja Biopharma, Inc.'s investors?
- Umoja Biopharma, Inc.'s investors include MPM BioImpact, DCVC Bio, Qiming Venture Partners USA, SoftBank Group, K2 HealthVentures, SoftBank Vision Fund, Alexandria, DCVC (Data Collective) and 1 more.
- How much funding has Umoja Biopharma, Inc. raised?
- Umoja Biopharma, Inc. has disclosed $210M raised across 1 of its 2 known rounds.
- Where is Umoja Biopharma, Inc. headquartered?
- Umoja Biopharma, Inc. is headquartered in Seattle, US.